sponsored
PatientsVille.com Logo

PatientsVille

Losartan Medical Research Studies

Up-to-date List of Losartan Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Losartan Medical Research Studies

Rank Status Study
1 Recruiting Losartan for Sickle Cell Kidney Disease
Condition: Sickle Cell Disease
Intervention:
Outcome Measures: Effects of Losartan;   chronic angiotensin blockade
2 Unknown  The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients
Condition: Peritoneal Membrane Failure
Interventions: Drug: placebo;   Drug: Aliskiren;   Drug: Aliskiren plus Losartan;   Drug: Enalapril plus Losartan
Outcome Measures: Changing in modified peritoneal equilibrium test;   appearance rate of dialysate CA125;   nutritional status;   adverse events
3 Unknown  Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients
Condition: Marfan Syndrome
Interventions: Drug: Losartan and nebivolol;   Drug: Losartan;   Drug: Nebivolol
Outcome Measures: BSA and age-adjusted aortic root diameter (sinuses of Valsalva);   The pharmacokinetics of the two drugs by age and dosages;   Comparative evaluation of the serum levels of total and active TGFb;   Quantitative assessment of the expression of the mutated gene (FBN1, both 5' and 3');   Pharmacogenetic bases of drug responsiveness (Losartan: CYP2C9 gene) (Nebivolol: CYP2D6 gene);   Aortic valve regurgitation severity;   Left ventricular end-diastolic diameter;   Left ventricular ejection fraction;   Spirometric lung volumes and flows;   QoL evaluation basing on SF-36 questionnaire;   Arterial stiffness (carotids)
4 Recruiting Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
Condition: Nonalcoholic Steatohepatitis
Intervention: Drug: Losartan
Outcome Measures: The primary outcome will be change in Kleiner fibrosis score, [Kleiner DE et al Hepatology 2005], based on histological fibrosis stage (as judged by two independent blinded histopathologists from liver biopsies), from pre-treatment to end-of-study;   Change in radiological (fibroscan) and serological (ELF) markers of fibrosis;   change in NAFLD activity score (NAS);   comparison of "responder rate" - placebo versus intervention
5 Recruiting Study of Losartan in the Treatment of NAFLD in Children
Condition: NAFLD
Intervention: Drug: Losartan
Outcome Measures: Change in ALT from baseline to week 8 and/or week 22;   Changes in cholesterol and fatty acid levels;   Changes in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR), insulin and glucose;   Changes in Plasminogen activator inhibitor-1 (PAI-1)
6 Not yet recruiting Comparison of Losartan Associated With Indapamide Versus Indapamide for Treatment of Hypertension
Condition: Hypertension
Interventions: Drug: Indapamide / Losartan;   Drug: Indapamide
Outcome Measures: Changes in systemic blood pressure measurements during 12 weeks;   Percentage (%) of patients with blood pressure < 140 / 90 mmHg during 12 weeks, will be obtained comparing the differences between initial blood pressure (initial visit) and final (final visit).;   Percentage (%) of patients excluded from the study because of treatment failure;   Time to appropriate control of systolic blood pressure and diastolic blood pressure (BP <140/90 mmHg.;   Incidence of any adverse events;;   Incidence of hypotension;   Incidence of serious adverse events and unexpected drug reactions
7 Recruiting Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: FOLFIRINOX;   Drug: Losartan;   Radiation: Proton Beam Radiation
Outcome Measures: Feasibility of combining FOLFIRINOX-Losartan;   Progression-Free Survival;   Overall Survival for FOLFIRINOX + Proton Beam Radiation;   Overall Survival for FOLFIRINOX Without Proton Radiation;   Determine Toxicity FOLFIRINOX-Losartan;   Determine Toxicity of FOLFIRINOX-Losartan and Proton Beam Radiation;   Rate of Downstaging;   Determine correlation of Somatic Gene Mutations and Outcome;   Determine Correlation Between Circulating Biomarkers and Outcome
8 Recruiting Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Losartan;   Drug: Placebo
Outcome Measures: The primary endpoint is to determine the impact of Losartan treatment on lymphoid tissue (LT) fibrosis.;   We will assess the impact of Losartan on immune reconstitution and function.;   We will determine the impact of Losartan on immune activation in HIV infected, treated individuals.;   We will assess the potential for Losartan to reduce the size of the viral reservoir.;   We will assess for any potential drug-drug interactions between Losartan and antiretrovirals (ARVs).
9 Recruiting Comparision of Blood Pressure Variability Between Amlodipine and Losartan
Condition: Hypertension
Interventions: Drug: Amlodipine;   Drug: Losartan
Outcome Measures: SD of visit-to-visit systolic blood pressure variability;   Central systolic blood pressure;   Augmentation index of central blood pressure;   Standard deviation of within-visit systolic blood pressure variability;   Coefficient of variation of visit-to-visit systolic blood pressure variability;   Variation independent of the mean of visit-to-visit systolic blood pressure variability;   24-h ambulatory blood pressure monitoring;   Home systolic blood pressure
10 Recruiting Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment
Conditions: Hypertension;   Sleep Apnea
Interventions: Drug: Losartan;   Other: CPAP
Outcome Measures: 24 h blood pressure (mean blood pressure; mmHg);   Markers of sympathetic activity, RAAS-activity, cardiovascular biomarkers
11 Recruiting Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
Conditions: Eosinophilic Esophagitis;   Connective Tissue Disorders
Intervention: Drug: Losartan Potassium
Outcome Measures: Number of participants with reduction of esophageal eosinophils;   Number of participants with reduction in levels of the transforming growth factor beta protein.;   Number of participants that experience normalization of the EoE transcriptome;   Number of participants that have an improved score utilizing the Patient Reported Outcome questionnaires to assess for clinical symptom response.;   Number of participants that have an improved score on the histology scoring system.;   To determine the safety of Losartan
12 Recruiting The Effect of Losartan in Bicuspid Aortic Valve Patients
Conditions: Bicuspid Aortic Valve;   Thoracic Aortic Aneurysm
Intervention: Drug: Cozaar
Outcome Measure: Inflammatory markers level
13 Unknown  A Randomized, Open-label, Losartan Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
Condition: Marfan Syndrome
Interventions: Drug: Losartan and Atenolol or Propranolol;   Drug: Atenolol or Propranolol
Outcome Measure: Echocardiograms
14 Unknown  Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations
Condition: Essential Hypertension
Interventions: Drug: Rostafuroxin;   Drug: Losartan
Outcome Measures: Systolic Blood Pressure;   Diastolic blood pressure;   Trough-to-peak ratio on Systolic Blood Pressure;   Number of participants with adverse events
15 Recruiting Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers
Condition: Marfan Syndrome
Interventions: Drug: Losartan;   Drug: Placebo
Outcome Measures: The decrease of rate of aortic root growth measured by echocardiography at level of sinuses of Valsalva. The measure will be expressed in mm of growth per year and as Z-score.;   Comparative arterial stiffness;   Evaluation of progression of aortic regurgitation;   Aortic dissection incidence;   Aortic root surgery;   Progression of mitral regurgitation;   Left ventricular size and function;   Skeletal and somatic traits;   Quality of life;   Genetic polymorphisms affecting clinical symptoms and response to treatment;   Death;   Aortic stiffness as assessed by MRI
16 Recruiting Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency
Condition: Renal Insufficiency, Chronic
Interventions: Drug: Benazepril;   Drug: Losartan;   Drug: Benazepril+Losartan
Outcome Measures: The proportion of patients with increase in serum potassium ≥6.0 mmol/L.;   The proportion of patients with serum creatinine increase >30%;   The proportion of patients with drug-related cough;   The proportion of patients with hopotension (systolic blood pressure <110 mmHg despite withdrawal of all additional antihypertensive medication);   The proportion of patients with non-fatal cardiovascular events
17 Unknown  PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites
Condition: Hypertension
Intervention: Drug: Losartan
Outcome Measure:
18 Recruiting Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated
Condition: HIV-1
Interventions: Drug: EFV/FTC/TDF + Losartan;   Drug: EFV/FTC/TDF;   Drug: FTC/TDF + MK-0518;   Drug: FTC/TDF+MK-0518+Losartan
Outcome Measures: Proportion of patients with 50% reduction of fibrosis in lymphatic tissue.;   Proportion of patients with changes in the levels of IL-6, D-dimer and CRP in different groups.;   Proportion of patients with increased CD4 in peripheral blood and in lymphatic tissue.;   Proportion of patients with undetectable plasma viral load and decreased in lymphatic tissue in different groups;   Proportion of patients with changes in the CD4/CD8 ratio in peripheral blood in different groups.;   Proportion of patients with reduced intima-media complex in carotid ultrasound in different groups.;   Proportion of patients with changes in levels of metalloproteinases and their inhibitors, beta2-microglobulin and CSF cells and proteins.;   Proportion of patients with improvement in neuropsychological test CDS;   Incidence and types of adverse events and laboratory abnormalities in the different groups.
19 Unknown  Effect of Lacidipine and Losartan on 24 Hour Systolic Blood Pressure Variability in Elderly Hypertensive Patients
Condition: Hypertension
Intervention: Drug: lacidipine (4 mg) or Losartan (50 mg)
Outcome Measures: The change of 24-hour, one day systolic BP standard deviation (SD) within subjects (the difference of SD before and after 12 weeks' treatment) in lacidipine group and Losartan group;   The change of 24-hour, one day diastolic BP standard deviation (SD) within subjects (the difference of SD before and after 12 weeks' treatment) in lacidipine group and Losartan group;   The difference of the changes in office diastolic and systolic BP after 12 weeks' treatment between lacidipine group and Losartan group;   The difference of the mean 24-hour ABPM systolic and diastolic BP after 12 weeks' treatment between lacidipine group and Losartan group;   The difference of the diastolic and systolic BP control rates after treatment between the 2 groups;   The difference of the changes in 24-hour, one day BP standard deviation (SD) within subjects between lacidipine group and Losartan group;   The difference of the variation of coefficient (CV) of the mean values (24-hour BP SD divided by the mean multiplied by 100) between 2 groups;   The difference of the smoothness index (SI, dividing the average of the 24 hourly change after treatment by the corresponding standard deviation) between 2 groups;   The difference of the changes in pulse pressure after treatment between the 2 groups
20 Unknown  The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients
Condition: Continuous Ambulatory Peritoneal Dialysis
Interventions: Drug: Enalapril;   Drug: Enalapril plus Losartan;   Drug: Placebo
Outcome Measures: Change in dialysate CA-125 and modified peritoneal equilibrium test;   Dialysis adequacy, residual renal function, hospitalization, peritonitis episodes, any adverse drug effects, death from any cause

These studies may lead to new treatments and are adding insight into Losartan etiology and treatment.

A major focus of Losartan research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Losartan